Several targeted agents are now approved or in clinical trials for subsets of AML with specific mutations or genetic changes (e.g., IDH1, IDH2, FLT3 ITD, FLT3 TKD, NPM1 mutations or KMT2A rearrangement), highlighting the importance of incorporating multigene mutation panel testing in precision oncology trials [48].Additionally, TP53 mutated AML is associated with dismal outcomes, which may not improve with the addition of drugs such as venetoclax, thus requiring a separate clinical trial when possible [51]. Here, IDH2 is linked to acute myeloid leukemia.